Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1

  1. Shoumo Bhattacharya1,
  2. Catherine L. Michels,
  3. Man-Kit Leung,
  4. Zoltàn P. Arany,
  5. Andrew L. Kung, and
  6. David M. Livingston2
  1. The Dana-Farber Cancer Institute and the Harvard Medical School, Boston, Massachusetts 02115 USA

Abstract

Recruitment of p300/CBP by the hypoxia-inducible factor, HIF-1, is essential for the transcriptional response to hypoxia and requires an interaction between the p300/CBP CH1 region and HIF-1α. A new p300-CH1 interacting protein, p35srj, has been identified and cloned. p35srj is an alternatively spliced isoform of MRG1, a human protein of unknown function. Virtually all endogenous p35srj is bound to p300/CBP in vivo, and it inhibits HIF-1 transactivation by blocking the HIF-1α/p300 CH1 interaction. p35srj did not affect transactivation by transcription factors that bind p300/CBP outside the CH1 region. Endogenous p35srj is up-regulated markedly by the HIF-1 activators hypoxia or deferoxamine, suggesting that it could operate in a negative-feedback loop. In keeping with this notion, a p300 CH1 mutant domain, defective in HIF-1 but not p35srj binding, enhanced endogenous HIF-1 function. In hypoxic cells, p35srj may regulate HIF-1 transactivation by controlling access of HIF-1α to p300/CBP, and may keep a significant portion of p300/CBP available for interaction with other transcription factors by partially sequestering and functionally compartmentalizing cellular p300/CBP.

Keywords

Footnotes

  • 1 Present address: Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK.

  • 2 Corresponding author.

  • E-MAIL David_Livingston{at}dfci.harvard.edu; FAX (617) 632-4381.

    • Received August 14, 1998.
    • Accepted November 17, 1998.
| Table of Contents

Life Science Alliance